Categoria: Letteratura

Autori: Harbeck  N, Wrobel D, M. Zaiss M, et al. Background: Neratinib is registered in Europe as extended adjuvant treatment for adult patients with Human Epidermal Growth Factor Receptor 2-positive (HER2+) and Hormone receptor-positive (HR+) eBC within one year after completed adjuvant trastuzumab-based therapy (“EMA-/Swiss-label” population). In the ExteNET trial, extended adjuvant neratinib improved the...

Autori: Curigliano  G, Dunton   K,  Rosenlund M, et al. Background: In DESTINY-Breast03 (NCT03529110), T-DXd showed superior progression-free survival by BICR vs T-DM1 (HR, 0.28 [95% CI, 0.22-0.37]; P < 0.001) and manageable safety in pts with HER2+ MBC. PRO measures incorporate pts’ perspective in clinical trials to assess effect of treatment on health-related quality of...

Autori: Bartsch  R, Berghoff AS, Furtner J, et al. Background: Brain metastases (BM) are a frequent and devastating complication of HER2-positive breast cancer (BC). T-DXd is an antibody-drug conjugate with high activity in pretreated pts but information regarding activity in active BM is limited. Therefore, the prospective, single-arm, phase II TUXEDO-1 trial investigated T-DXd in...

Autori: Chan A, Ruiz Borrego M, Marx  G, et al. Background: Neratinib (N), an irreversible pan-HER TKI, is approved in the EU for extended adjuvant treatment of early-stage HR+ HER2+ breast cancer (BC) after adjuvant trastuzumab (T)-based therapy. The CONTROL trial (NCT02400476) investigated pre-emptive antidiarrheal prophylaxis or dose escalation (DE) for prevention of diarrhea, the...

Autori: Cescon DW, Schmid P, Rugo HS, et al.   Background: KEYNOTE-355 (NCT02819518) evaluated pembro + chemo vs pbo + chemo in previously untreated patients (pts) with locally recurrent inoperable or metastatic TNBC. Pembro + chemo improved the PFS and OS in pts with PD-L1 combined positive score (CPS) ≥10 disease. We present results for...

Autori: Gebhart G, Keyaerts M, Guiot T, et al. Background: PHERGain trial investigated the potential of metabolic imaging to identify candidates for chemotherapy (CT) de-escalation in HER2-positive, stage I-IIIA, invasive, operable breast cancer with at least one breast lesion evaluable by FDG-PET. Based on data from NeoALTTO study, FDG-PET “responders” were defined as those pts...

Autori: Ahn HK, Park K, Sim SH, et al. Background: Neoadjuvant atezolizumab plus docetaxel, trastuzumab and pertuzumab therapy showed favorable efficacy and safety profiles in HER2-positive early breast cancer (EBC) in NEO-PATH phase 2 study, which provided evidence of combining immunotherapy and anti-HER2 treatment as a potential new therapeutic option. We evaluated potential genomic biomarkers...

Autori: Viale  G, Bonizzi G, Capra M, et al. Background: Establishing biobanking in cancer research is important for health research infrastructure to collect, store, process, and distribute high-quality human biological samples and associated data. The Biobank for Translational Medicine (B4MED) Unit at the European Institute of Oncology (IEO) is a landmark in this field. The...

Autori: Di Cosimo S, Ciniselli CM, Sotiriou C, et al. Background: With increasing evidence showing the complexity of HER2-positive breast cancer, this study aimed to identify a gene-expression signature with potential prognostic value to assist therapeutic decision in the early disease setting. Methods: Gene-expression profiles of NeoALTTO tumor biopsies before and after 2 weeks of...

Autori: Neven P, Fasching  PA, Chia P, et al. Background: The MONALEESA-3 (NCT02422615) final protocol-specified OS analysis and an exploratory OS analysis with extended follow-up demonstrated significant OS benefit with RIB + FUL vs placebo (PBO) + FUL as 1L or second-line (2L) treatment (tx). At the time of these analyses, the median (m) OS...